Crinetics Pharmaceuticals (CRNX) Proxy filing summary

Executive summary

• Shareholders are asked to vote on a merger agreement where the company will be acquired by Vertex Pharmaceuticals for $85.00 per share in cash, representing a significant premium over recent trading prices.

• The merger will result in the company becoming a wholly owned subsidiary of Vertex, with shares delisted from Nasdaq and deregistered under the Exchange Act.

• The board unanimously recommends voting in favor of the merger, the related executive compensation, and the potential adjournment of the meeting if more votes are needed.

• The merger is expected to close in the third quarter of 2026, subject to regulatory and shareholder approvals.

Voting matters and shareholder proposals

• Shareholders will vote on: (1) adoption of the merger agreement, (2) a non-binding advisory vote on executive compensation related to the merger, and (3) adjournment of the meeting if necessary to solicit additional votes.

• Approval of the merger requires a majority of outstanding shares; failure to vote or abstentions count as votes against the merger.

• The compensation proposal is advisory and not a condition to closing; the adjournment proposal allows for additional time to secure votes if needed.

Board of directors and corporate governance

• The board, after consulting with financial and legal advisors, determined the merger is fair and in the best interests of shareholders.

• The board conducted a robust negotiation process, solicited interest from other potential acquirers, and received fairness opinions from J.P. Morgan and Leerink Partners.

• No other strategic alternatives were deemed superior to the Vertex offer after outreach to multiple parties.